Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy - Wikidata - awgldk - TriplyDB

Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy

Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy

http://www.wikidata.org/entity/Q28304033

about

Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphoma Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors.Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Updated Review of Clinical Outcomes and the Molecular Pathogenesis Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond.Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial Successful treatment of mucosa-associated lymphoid tissue lymphoma in a patient with gastric and rectal lesions with metachronous and ectopic development.Monoclonal antibody therapy of leukaemias and lymphomas.Treatment of gastric mucosa-associated lymphoid tissue lymphoma: Helicobacter pylori eradication and beyond.Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management.Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists.Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?Radiotherapy for low-grade gastric marginal zone lymphoma: a retrospective study.Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database Therapy of gastric mucosa-associated lymphoid tissue lymphoma.Therapy of gastric mucosa associated lymphoid tissue lymphoma.Therapeutic management of ocular adnexal MALT lymphoma.Primary rectal mucosa-associated lymphoid tissue lymphoma in a patient with previously identified primary biliary cirrhosis and secondary Sjögren's syndrome.Early, Isolated Duodenal Mucosa-Associated Lymphoid Tissue Lymphoma Presenting without Symptoms or Grossly Apparent Endoscopic Lesions and Diagnosed by Random Duodenal Biopsies.Primary duodenal mucosa-associated lymphoid tissue (MALT) lymphoma--a rare presentation of gastric outlet obstruction Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management.Epidemiology, pathology and treatment of non-follicular indolent lymphomas.Primary B-Cell Mucosa-Associated Lymphoid Tissue Lymphoma of the Hard Palate and Parotid Gland: Report of One Case and Review of the Literature.Antivascular agents for non-small-cell lung cancer: current status and future directions.Treatment of gastric marginal zone lymphoma of MALT type.Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type.Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication.Clinical aspects of malt lymphomas.Uncommon non-Hodgkin lymphomas of childhood: pathological diagnosis, clinical features and treatment approaches.Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.Primary hepatic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type: A case report and literature review.Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin's lymphoma.Radiotherapy for localized gastric mucosa-associated lymphoid tissue lymphoma: long-term outcomes over 10 years.Rituximab in the treatment of non-Hodgkin's lymphoma Gastric MALT lymphoma: old and new insights.

P2860

Q26741090-D4B99775-EC31-40BE-B5EB-605F6591FD4A Q26771654-EEA76E6B-A46F-4943-B5DD-541F5AAB0E2B Q26851987-5A554E6A-D753-4ED2-AFA8-E6E936691E7F Q33391725-305B8C2F-82D1-4B97-9FDE-937056A95B2C Q33418199-78502E12-0567-4C23-8271-639A7CFB6A0C Q33626074-7604E73C-44D5-4009-AAC6-6788F72325DF Q33781603-0396D3F6-A742-4749-8664-7600BDB6EFFA Q34389619-E703DB0E-5C95-4F15-80E5-1752389103F3 Q34600972-6580D040-3E75-4D4D-AF0A-A5312F1709F4 Q35093241-9F9D0D9B-F2AC-487B-97C4-DF7CBD8C0E95 Q36239669-CDC90821-3F90-4F99-BD06-13136E39CFC8 Q36407449-E9E07AD5-A901-4FC4-8F35-255AFE8946EC Q36477917-A09B6AE1-0A62-4D64-BE3C-AF405BBE8688 Q36584820-8C7D0A83-B725-4189-9503-E40C8B1B1EC3 Q36677699-8986855E-71D3-42CF-9D4B-088B446117E1 Q36742694-7B18E749-3451-45A4-998C-D89E44373F54 Q36768594-E744AB2C-28AA-42C8-A3A8-C9E2605DDE93 Q36777008-E96F17F3-63AF-4BE9-A49E-2858AD590F20 Q36847291-4ECBCB2B-642C-47F4-97E8-83C3BF2A03BC Q36894785-2B59B9A7-4852-4637-9111-1DE18C306DBC Q36964741-88D20223-6AE7-4374-9D56-32442D91C121 Q36990119-79C442BB-1E0A-4D1F-984A-820E25249AC9 Q37096322-82055F18-461E-43E2-B044-39282B895896 Q37134504-E2885A7F-AA8D-41A2-BF37-1C5F39B802E4 Q37224102-9C41EF6B-54D2-4FC2-8841-984A6B7099C6 Q37280928-35FFE7D2-C405-4F77-A189-372403C49E3C Q37304570-D841A102-B039-4E35-9C00-8A50266B5E3D Q37624732-83D42233-8EEA-4439-8BB1-E59C5C1DD95A Q37768456-A1BF9B04-01FD-4F57-8263-43188B43DB68 Q37944372-DE0797D9-94D0-4058-A3CD-0E90130BE0D9 Q38100784-9EFD71E5-5B6B-42A9-9F6F-42C530006E00 Q38101527-DCE43FF1-FDDE-44A7-902C-F75A3CB9AB80 Q38252813-1E1E0EF1-2D5C-41CB-BDFC-CC84B9598F8F Q38410415-375EB6A7-6C95-4857-963B-D5A9CCAAE999 Q38544142-8E18855F-290A-4FA2-B1A5-3F002F83BF6B Q39206620-BB0E8F08-AEF4-400E-8C8C-3A576EAD70DA Q39690225-76AEBBD6-F918-4926-8B78-C52D38A791AD Q41511282-5B5B2572-23F2-497E-9D13-1C52A8E52A76 Q41925899-EEA00513-5B3B-4AC3-BC40-FAFCA57C2C83 Q42406504-12FA8FEE-8E36-4390-BFD3-B9498832E837

P2860

Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy

http://www.wikidata.org/entity/Q28304033

description

2005 nî lūn-bûn

@nan

2005 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մարտին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Clinical activity of rituximab ...... ti-Helicobacter pylori therapy

@ast

Clinical activity of rituximab ...... ti-Helicobacter pylori therapy

@en

Clinical activity of rituximab ...... ti-Helicobacter pylori therapy

@nl

type

label

Clinical activity of rituximab ...... ti-Helicobacter pylori therapy

@ast

Clinical activity of rituximab ...... ti-Helicobacter pylori therapy

@en

Clinical activity of rituximab ...... ti-Helicobacter pylori therapy

@nl

prefLabel

Clinical activity of rituximab ...... ti-Helicobacter pylori therapy

@ast

Clinical activity of rituximab ...... ti-Helicobacter pylori therapy

@en

Clinical activity of rituximab ...... ti-Helicobacter pylori therapy

@nl

P1433

Q28304033-3717DFF9-716D-4A80-A1E4-1C5FDC5645DE

P1476

Q28304033-9F2A2D1A-B188-4D43-A5BB-8F83406985A8

P2093

Q28304033-1C54F248-020B-4648-856A-786B44597096

Q28304033-21AC212E-B332-449B-ABB9-225342A215B2

Q28304033-31F879FC-C0B0-4E5B-A709-7F4875ABD31E

Q28304033-45C68A11-0831-438E-BE60-550E78F937B4

Q28304033-6A201B53-A341-4679-AE1E-DF130D3B4C4C

Q28304033-7082593C-D876-4F8F-AB5E-4A00DF485A39

Q28304033-9C5CAC60-652B-4B73-A121-462F28A0F4DC

Q28304033-A68516B1-4C23-4FB6-89DA-14726779DC25

Q28304033-D5F96747-3111-4E99-A3DD-149BB803D47F

Q28304033-E2C67349-A9AA-4B40-BAB3-51AFA061DA54

P304

Q28304033-B8573D82-AAD8-4FF3-948B-30A4CC723D17

P31

Q28304033-692FD082-062B-4BBD-BA08-02E2A0ADF9C4

P3181

Q28304033-AE85D201-B5A9-4406-B048-E8EA7AB59E49

P356

Q28304033-2F1F280F-A5F1-4A44-B264-73974BF66333

P407

Q28304033-3CD76E9D-9F99-444E-BB23-DF24B3DC931F

P433

Q28304033-66F6B332-F321-4DD0-8F45-AB92AB1ADED0

P478

Q28304033-382C16F2-8A59-40A4-84AB-F568FFFEA424

P50

Q28304033-FF6E0908-F0EF-4500-BC81-93B9C8A5E6F6

P577

Q28304033-C5EE1289-8988-4E5B-9167-31BB2400FD90

P698

Q28304033-B2287A2B-AD66-439F-B432-1FABE903343F

P921

Q28304033-0A0882B8-6571-496A-AF15-4F25C3A66487

P3181

P356

JCO.2005.08.128

P1433

Journal of Clinical Oncology

P1476

Clinical activity of rituximab ...... ti-Helicobacter pylori therapy

@en

P2093

Andrés J M Ferreri

http://www.w3.org/2001/XMLSchema#string

Annarita Conconi

http://www.w3.org/2001/XMLSchema#string

Cristiano Crosta

http://www.w3.org/2001/XMLSchema#string

Daniele Laszlo

http://www.w3.org/2001/XMLSchema#string

Emanuele Zucca

http://www.w3.org/2001/XMLSchema#string

Ennio Pedrinis

http://www.w3.org/2001/XMLSchema#string

Francesco Bertoni

http://www.w3.org/2001/XMLSchema#string

Giancarlo Pruneri

http://www.w3.org/2001/XMLSchema#string

Liliana Calabrese

http://www.w3.org/2001/XMLSchema#string

Maurilio Ponzoni

http://www.w3.org/2001/XMLSchema#string

P304

1979-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1916616

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2005.08.128

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Martinelli

P577

2005-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15668468

http://www.w3.org/2001/XMLSchema#string

P921

Helicobacter pylori